Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas

Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the imm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danza,Álvaro, Graña,Diego, Goñi,Mabel, Vargas,Andrea, Ruiz-Irastorza,Guillermo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2016
Materias:	Antiphospohlipid syndrome Autoimmune diseases Hydroxychloroquine systemic lupus erythematosus Rheumatoid arthritis Sjögren’s syndrome
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200012
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872016000200012
record_format	dspace
spelling	oai:scielo:S0034-988720160002000122016-04-13Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicasDanza,ÁlvaroGraña,DiegoGoñi,MabelVargas,AndreaRuiz-Irastorza,Guillermo Antiphospohlipid syndrome Autoimmune diseases Hydroxychloroquine systemic lupus erythematosus Rheumatoid arthritis Sjögren’s syndrome Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjögren’s syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.144 n.2 20162016-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200012es10.4067/S0034-98872016000200012
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antiphospohlipid syndrome Autoimmune diseases Hydroxychloroquine systemic lupus erythematosus Rheumatoid arthritis Sjögren’s syndrome
spellingShingle	Antiphospohlipid syndrome Autoimmune diseases Hydroxychloroquine systemic lupus erythematosus Rheumatoid arthritis Sjögren’s syndrome Danza,Álvaro Graña,Diego Goñi,Mabel Vargas,Andrea Ruiz-Irastorza,Guillermo Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
description	Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. It has immunomodulatory, hypolipidemic, hypoglycemic and antithrombotic properties and it diminishes the risk of malignancies. The most important mechanisms to explain the immunomodulatory actions are its ability to reduce inflammatory pathways and Toll-like receptors activation. The safety profile is favorable. In spite of its low frequency, retinal toxicity is potentially severe. In systemic lupus erythematous HCQ therapy reduces activity, the accrual of organ damage, risk of infections and thrombosis and improves the cardiometabolic profile. It contributes to induce lupus nephritis remission, spares steroid use and increases survival rates. In rheumatoid arthritis, it improves cardiometabolic risk and has a favorable effect in joint inflammation. In Sjögren’s syndrome, an increased lacrimal quality as well as an improvement in objective and subjective inflammatory markers has been demonstrated with HCQ. In Antiphospholipid Syndrome, HCQ is effective in primary and secondary thrombosis prevention. The effectiveness of the drug in other systemic autoimmune diseases is less established. HCQ therapy may improve dermatological manifestations in Dermatomyositis and may have a positive effects in the treatment of Sarcoidosis and Still disease.
author	Danza,Álvaro Graña,Diego Goñi,Mabel Vargas,Andrea Ruiz-Irastorza,Guillermo
author_facet	Danza,Álvaro Graña,Diego Goñi,Mabel Vargas,Andrea Ruiz-Irastorza,Guillermo
author_sort	Danza,Álvaro
title	Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
title_short	Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
title_full	Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
title_fullStr	Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
title_full_unstemmed	Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
title_sort	hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas
publisher	Sociedad Médica de Santiago
publishDate	2016
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200012
work_keys_str_mv	AT danzaalvaro hidroxicloroquinaeneltratamientodelasenfermedadesautoinmunessistemicas AT granadiego hidroxicloroquinaeneltratamientodelasenfermedadesautoinmunessistemicas AT gonimabel hidroxicloroquinaeneltratamientodelasenfermedadesautoinmunessistemicas AT vargasandrea hidroxicloroquinaeneltratamientodelasenfermedadesautoinmunessistemicas AT ruizirastorzaguillermo hidroxicloroquinaeneltratamientodelasenfermedadesautoinmunessistemicas
_version_	1718436866908225536

Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas

Ejemplares similares